Antivirals Market Trends Are Creating New Opportunities For Industry Leaders
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Antivirals Market Growth Analysis: How Will Revenue Expand During The Forecast Period?
The market for antivirals has experienced robust expansion in recent years, with projections indicating an increase from $114.4 billion in 2025 to $122.08 billion in 2026, representing a compound annual growth rate (CAGR) of 6.7%. This historical growth has been driven by factors such as worldwide viral epidemics, the high prevalence of HIV and hepatitis, government initiatives involving antiviral stockpiling, the widespread availability of generic medications, and the extension of infectious disease management programs.
Projections indicate that the antivirals market will continue its robust expansion in the coming years, reaching $163.33 billion by 2030 with a compound annual growth rate of 7.5%. Key drivers behind this forecasted growth include the emergence of new viral threats, heightened investment in antiviral research and development, greater alignment between vaccination programs and treatment strategies, global health initiatives, and a pressing need for therapeutics that can be deployed rapidly. Notable trends shaping the market involve a growing preference for broad-spectrum antivirals, an intensified emphasis on pandemic readiness, a wider availability of generic antiviral medications, expanded application in managing chronic viral infections, and the advancement of antivirals operating through novel mechanisms.
Download A Free Sample Report For Comprehensive Market Insights:
Antivirals Market Growth Drivers And Industry Catalysts
The growing number of influenza cases is expected to drive expansion in the antiviral market moving forward. Influenza, commonly referred to as the flu, is a highly contagious viral respiratory illness caused by influenza viruses that impact the nose, throat, and lungs. This rise in flu prevalence is largely attributed to colder temperatures and indoor gatherings, which enable the virus to persist longer and increase transmission among people in close quarters. Antivirals are employed to treat influenza by preventing the replication and spread of these viruses throughout the body. As an example, in November 2024, the Centers for Disease Control and Prevention, a US-based national public health agency, reported that the 2023 to 2024 flu season was linked to an estimated 40 million illnesses, 18 million medical visits, 470,000 hospitalizations, and 28,000 deaths. Consequently, the escalating incidence of influenza is fueling the growth of the antiviral market.
Antivirals Market Segmentation: How Is The Market Structured Across Key Categories?
The antivirals market covered in this report is segmented –
1) By Type: Branded, Generic
2) By Drug Class: DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Other Drug classes
3) By Application: HIV, Hepatitis, Herpes, Influenza, Other Applications
Subsegments:
1) By Branded: Antivirals For HIV Or AIDS, Antivirals For Hepatitis, Antivirals For Influenza, Antivirals For Herpes Simplex Virus (HSV)
2) By Generic: Generic HIV Or AIDS Antivirals, Generic Hepatitis Antivirals, Generic Influenza Antivirals, Generic Herpes Simplex Virus (HSV) Antivirals
Antivirals Market Trends Influencing Long-Term Demand
Leading players within the antiviral market are concentrating their efforts on creating cutting-edge therapies like oral antiviral medications aimed at boosting patient adherence, improving accessibility, lowering healthcare expenses, and delivering more convenient and effective solutions for managing viral diseases. An oral antiviral treatment is a medication taken by mouth that targets viral infections. These drugs function by preventing viruses from replicating or disseminating throughout the body, thereby lessening infection severity and duration. For example, in May 2023, Pfizer—a pharmaceutical company headquartered in the US—secured approval for Paxlovid, designating it as the first oral antiviral for COVID-19 in adults from the Food and Drug Administration, a US government entity. This endorsement holds particular importance as it introduces a fresh therapeutic choice for controlling COVID-19, especially as the pandemic shifts toward an endemic stage. Paxlovid is specifically intended for adults experiencing mild-to-moderate COVID-19 who face a heightened risk of advancing to severe illness, including hospitalization or death.
Key businesses active in the antiviral sector are emphasizing the development of sophisticated therapeutic approaches, like antiviral treatments, to improve patient results and curb viral spread. Antiviral therapies play a critical role in managing viral infections and averting complications in afflicted individuals. As an illustration, in August 2024, Red Queen’s Technology, a US-based pharmaceutical firm, introduced versatile antivirals. Apple Tree Partners committed $55 million to Red Queen Therapeutics, a biotech enterprise creating broad-spectrum antiviral solutions. The company addresses infectious agents such as COVID-19 and influenza, having already advanced a COVID antiviral through Phase 1 clinical trials and obtained US government support for a pan-influenza medication. Co-founded by Harvard professor Loren Walensky, Red Queen utilizes stapled lipopeptides to impede viral fusion and block viral entry into host cells.
Antivirals Market Competitive Landscape And Leading Companies
Major companies operating in the antivirals market are AbbVie Inc., Bristol-Myers-Squibb Co., Chemical Industrial & Pharmaceutical Laboratories Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Ltd., Merck & Co. Inc., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Abbott Laboratories, Schering-Plough Corporation, Pfizer Inc., Sanofi-Synthélabo Ltd., Inovio Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., AVI Biopharma International Ltd., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Biogen Inc., Genentech USA Inc., Vertex Pharmaceuticals Inc.
Access The Complete Antivirals Market Report:
Antivirals Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the anti-viral drug therapy market in 2025. The Middle East is expected to be the fastest-growing region in the antivirals market during the forecast period. The regions covered in the antivirals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
